Invest now

Sun Pharmaceutical Industries share price

Moderate risk
  • 16%Low risk
  • 16%Moderate risk
  • 16%Balanced risk
  • 16%High risk
  • 16%Extreme risk
  • ₹1,880.90(-0.31%)
    November 13, 2026 15:50:13 PM IST
    • NSE
    • BSE
  • Vol : 2.10 M (NSE + BSE)
    Last 20 day avg : 2.44 M
Sun Pharmaceutical Industries is trading -0.31% lower at Rs 1,880.90 as compared to its last closing price. Sun Pharmaceutical Industries has been trading in the price range of 1,914.95 & 1,870.00. Sun Pharmaceutical Industries has given 9.61% in this year & 3.06% in the last 5 days. Sun Pharmaceutical Industries has TTM P/E ratio 41.17 as compared to the sector P/E of 39.52.There are 32 analysts who have initiated coverage on Sun Pharmaceutical Industries. There are 10 analysts who have given it a strong buy rating & 18 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 1,988.53 Crores in its last quarter.Listed peers of Sun Pharmaceutical Industries include Divi's Laboratories (0.35%), Torrent Pharmaceuticals (-1.20%), Cipla (-1.21%).The Mutual Fund holding in Sun Pharmaceutical Industries was at 13.01% in 30 Sep 2026. The MF holding has increased from the last quarter. The FII holding in Sun Pharmaceutical Industries was at 14.36% in 30 Sep 2026. The FII holding has decreased from the last quarter.

Shares of Sun Pharmaceutical Industries fell by -0.74% (Rs. 970.05) at closing today at BSE. Today 0.16 Lac shares of the company were traded at BSE. At the current price, its market cap amounts to Rs. 2,34,571.0 Cr approximately.

Sun Pharmaceutical Industries shares have been trading in the price band of Rs. 968.3 and Rs. 978.5 at BSE today. At the day's low, its shares fell by -0.99% as compared to the previous close recorded of Rs. 977.28.

Benchmark indices Sensex (-0.69%) & Nifty (-0.77%) performed poorly at closing today. Sun Pharmaceutical Industries outperformed both of them.

Amongst its peers, Dr Reddys Laboratories rose 0.33%, Cipla was also up 0.86% and Aurobindo Pharma as well had a rise of 2.89% today.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Loading...
Key Metrics

Updated on 14 Nov 2026, 11:37 AM IST

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.80
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.06
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.85
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    4.39
    Indicates overvaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
Price range
Day Range
Lowest
1,870.00
Highest
1,914.95
52 week range
Lowest
1,583.60
Highest
2,047.55
Sun Pharmaceutical Industries Peers
Return Comparison
Peers Comparison
Names
Price%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Divi's Laboratories
11,489.650.353,05,014.1073.3211.480.410.03
Torrent Pharmaceuticals
4,662.15-1.201,77,326.8672.7319.220.80141.16
Cipla
1,393.00-1.211,12,534.6827.573.330.921.11
Zydus Lifesciences
1,191.00-1.201,18,802.7121.194.240.0914.22
Lupin
1,980.00-1.6990,538.6419.124.980.749.53
Mutual Fund Ownership
View all
WhiteOak Capital Pharma and Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 29.04
  • % of AUM 8.76
DSP Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 257.62
  • % of AUM 8.70
ICICI Prudential ESG Exclusionary Strategy Fund Regular Growth
5/5
  • Amount Invested (Cr.) 114.27
  • % of AUM 7.49
SBI Equity Minimum Variance Fund Regular Growth
NA
  • Amount Invested (Cr.) 15.98
  • % of AUM 7.40
ICICI Prudential MNC Fund Regular Growth
NA
  • Amount Invested (Cr.) 109.94
  • % of AUM 6.56
Sun Pharmaceutical Industries Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-10-30Quarterly Results
2026-10-12Others
2026-07-31Quarterly Results
2026-05-22Audited Results & Final Dividend
2026-01-31Quarterly Results & Interim Dividend
About the company Sun Pharmaceutical Industries
  • IndustryBiotechnology & Drugs
  • ISININE044A01036
  • BSE Code524715
  • NSE CodeSUNPHARMA
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty therapies, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.
  • Management Info
  • Dilip ShanghviExecutive Chairman of the Board
  • Jayashree SatagopanChief Financial Officer
  • Aalok ShanghviWhole-time Director and Chief Operating Officer
  • Anoop DeshpandeCompliance Officer, Company Secretary
  • Kirti GanorkarManaging Director
  • Vidhi ShanghviWhole-Time Director
Sun Pharmaceutical Industries Share Price FAQs

Sun Pharmaceutical Industries is trading at 1880.90 as on Fri Nov 13 2026 10:20:13. This is -0.31% lower as compared to its previous closing price of 1886.80.

The market capitalization of Sun Pharmaceutical Industries is 451290.91 Cr as on Fri Nov 13 2026 10:20:13.

The average broker rating on Sun Pharmaceutical Industries is Buy. The breakup of analyst rating is given below -

  • 10 analysts have given a strong buy rating
  • 18 analysts have given a buy rating
  • 1 analysts have given a hold rating
  • 2 analysts have given a sell rating
  • 1 analysts have given a strong sell rating

The 52 wk high for Sun Pharmaceutical Industries is 2047.55 whereas the 52 wk low is 1583.60

Sun Pharmaceutical Industries can be analyzed on the following key metrics -

  • TTM P/E: 41.17
  • Sector P/E: 39.52
  • Dividend Yield: 0.85%
  • D/E ratio: 0.04

Sun Pharmaceutical Industries reported a net profit of 11479.42 Cr in 2026.

The Mutual Fund Shareholding was 13.01% at the end of 30 Sep 2026.